Boston Scientific Corporation (BSX) Stock: Price, Forecast & Analyst Target
Boston Scientific Corporation (BSX) — MoonshotScore 77/100 (Strong band), calculated Nov 18, 2026. Price $42.99 (-1.49%), as of the Nov 19, 2026 trading session; market cap $62.3B. Expected results Feb 3, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Boston Scientific Corporation · BSX · NYSE · Healthcare · Medical - Devices
Research dated 2026-09-12: Boston Scientific sells procedure-specific devices used across cardiovascular care, rhythm management, endoscopy, urology and neuromodulation. Revenue is still rising, but its durability depends on cardiac rhythm management returning to growth and operating cash flow supporting a balance sheet where debt far exceeds liquid resources.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Boston Scientific (BSX)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and elite growth, though the balance sheet is only middling. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Compounding; Momentum: Quiet.
- EPS beat 0 of the last 4 reports
- expected results Feb 3, 2027
- Altman Z 3.01 · Piotroski F 6
Helping: business quality, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 80 | Exceptional | |
| 80 | Exceptional | |
| 81 | Exceptional | |
| 81 | Exceptional | |
| 77 | Strong | |
| 77 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $42.99 | |
| Change on the day | -1.49% | |
| 52-week range | $39.57–$101.91 | |
| Market capitalisation | $62.3B | — |
| Price / earnings (trailing) | 18.16 | |
| Shares traded on the day | 15.92M | |
| Beta (volatility vs the S&P 500) | 0.59 |
Why Boston Scientific scores 77
Share price, last 12 months -55.7%
$100.91 $44.70
What the price assumes
6.8% a year of free-cash-flow growth for ten years is what a $64.79B market value ( snapshot) asks for.
The price asks for less growth than the business has been producing. The question it leaves open is how long that pace lasts, not whether it exists. It also runs ahead of the analysts' revenue path.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $3.33B. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 11 of the last 12 reports (2024–2026); the stock still fell the next session after 4 of those beats. Average first-session move: 5.4% either way.
- +5.5%Jan ’24
- +6.2%Apr ’24
- -5.5%Jul ’24
- -3.3%Oct ’24
- +1.4%Feb ’25
- +6.4%Apr ’25
- +3.0%Jul ’25
- +2.5%Oct ’25
- -15.3%Feb ’26
- +10.4%Apr ’26
- -0.1%Jul ’26
- -5.3%Oct ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| In line | In line | -5.3% | +1.7% | |
| Beat | Beat | -0.1% | +3.6% | |
| Beat | In line | +10.4% | -4.0% | |
| Beat | In line | -15.3% | -19.8% | |
| Beat | Beat | +2.5% | +0.4% | |
| Beat | Beat | +3.0% | +3.5% | |
| Beat | Beat | +6.4% | +8.2% | |
| Beat | Beat | +1.4% | +2.2% | |
| Beat | Beat | -3.3% | -4.6% | |
| Beat | Beat | -5.5% | -6.0% | |
| Beat | Beat | +6.2% | +4.7% | |
| Beat | Beat | +5.5% | +6.2% |
Beats have usually been rewarded — 7 of 11 drew a higher close the next session.
What management is saying differently
Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.
- New this call: “cyber incident”, “cardiogenic shock”, “full-year adjusted”, “high growth” — none of them came up in Q2 FY2026.
- Getting louder: “gross margin” (3 → 7 mentions), “growth profile” (3 → 7 mentions), “supply chain” (2 → 6 mentions).
- Gone quiet: “eps growth”, “double-digit growth”, “laac market”, “margin expansion” — regular themes last call, absent this time.
The tone held steady from one call to the next; what changed is the subject matter, not the confidence.
Our track record on this stock
Since the score went from 80 to 77 while the share price moved -12.3% through .
| Date | Band | 3 months | 6 months | Call |
|---|---|---|---|---|
| Exceptional → Strong | — | — | — | |
| Strong → Exceptional | — | — | — | |
| Exceptional → Strong | — | — | — | |
| Strong → Exceptional | — | — | — | |
| Exceptional → Strong | — | — | — | |
| Strong → Exceptional | — | — | — |
None of the 12 band changes we have recorded has been graded yet; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 77% of 44 rate it a buy; the average target sits +27.1% from the price of $42.99.
- Last 90 days: 0 upgrades and 3 downgrades among 21 rating actions.
- Our signals: Strong band; strongest pillar Growth Durability (89), weakest Momentum (41).
Here we and the crowd agree.
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Boston Scientific (BSX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
The Munger lens reads the current price as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Boston Scientific (BSX), and what does it report?
Short answer · as of
Boston Scientific does not sell general hospital equipment.
Research dated 2026-09-12.
It commercializes catheters, stents, implants, mapping systems, stimulators and related accessories used by interventional specialties to diagnose or treat defined conditions; revenue therefore measures device sales rather than patient volumes or procedures themselves.
Reported segment revenue is grouped into Cardiovascular and MedSurg, with Cardiovascular providing the larger pool. Consolidated results blend product families serving different clinical pathways, so strength in vascular or structural-heart therapies can coexist with weakness in rhythm management, endoscopy or urology.
What do the latest results show for Boston Scientific (BSX)?
Research dated 2026-09-12.
The latest reported period brought higher revenue, gross profit and operating result than the preceding period, while net result and diluted earnings per share retreated. Separately, the estimate-comparison series recorded revenue and earnings above consensus again, extending an uninterrupted run across the displayed history.
Management frames revised guidance as a reset to a realistic baseline. It expects cardiac rhythm management to remain flat over the full year, with modest improvement later as EluPro contributes during its full launch.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $5.14B Oct 28, 2026
- Latest report · revenue estimate
- $5.09B Oct 28, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 28, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 28, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 28, 2026 | $5.14B | $5.09B | $0.7300 | $0.7270 |
| Jul 29, 2026 | $5.44B | $5.38B | $0.8600 | $0.8350 |
| Apr 22, 2026 | $5.20B | $5.17B | $0.8000 | $0.7880 |
| Feb 4, 2026 | $5.29B | $5.28B | $0.8000 | $0.7810 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $5.07B | $755M | $0.50 (diluted) |
| Q4 FY2025 | $5.29B | $672M | $0.45 (diluted) |
| Q1 FY2026 | $5.20B | $1.34B | $0.90 (diluted) |
| Q2 FY2026 | $5.44B | $907M | $0.61 (diluted) |
What are the financial strengths and risks for Boston Scientific (BSX)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Operating cash flow has remained positive and exceeded capital spending throughout the displayed periods, giving Boston Scientific meaningful internally generated funding. Profitability is also substantial at the gross, operating and net levels.
Cash and short-term investments have fallen markedly across the displayed window and sit far below total debt. Including long-term investments improves the liquidity picture but does not close that gap; current assets cover current liabilities, while immediately liquid coverage is thinner.
Cardiovascular supplies the larger reported revenue pool. Weaker adoption or use across coronary, peripheral vascular and structural-heart therapies would therefore have a disproportionate effect on companywide sales and cash generation.
What should you watch next at Boston Scientific (BSX)?
Short answer · as of
The next earnings report is expected on Feb 3, 2027.
Research dated 2026-09-12.
Consensus embeds sequential moderation in revenue and the earnings measure used for the scheduled release. Clearing that lower bar would matter less than the composition of the result: cardiac rhythm management should begin reflecting EluPro’s full launch if management’s expected improvement is taking hold.
Gross-profit conversion into operating profit, and operating profit into net income, deserve close attention after the latest divergence. Cash rebuilding also matters because recent operating cash generation was strong while cash and short-term investments remained well below debt.
A recent filing identified costs associated with exit or disposal activities. Any continuing effect should be assessed alongside management’s revised baseline rather than treated as evidence of underlying device demand.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Boston Scientific compare with its peers?
Short answer
Boston Scientific's score ranks 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Boston Scientific spans coronary and peripheral intervention, structural heart, rhythm management, endoscopy, urology, pelvic health, pain treatment and neurological stimulation. Its economic exposure is therefore broader than a focused cardiac-device franchise, yet more concentrated in interventional tools and implants than a general healthcare portfolio.
That breadth does not make the revenue mix even. Cardiovascular remains the larger reported segment, while MedSurg provides exposure to gastrointestinal, pulmonary, urological and pelvic-health procedures that follow different clinical pathways.
| Company | Price | Market value | Score |
|---|---|---|---|
| $105.23 Nov 18, 2026 | $60.5B | 93 5-pillar Nov 18, 2026 | |
| $80.19 Nov 19, 2026 | $29.9B | 93 5-pillar Nov 18, 2026 | |
| $320.00 Nov 19, 2026 | $12.6B | 92 5-pillar Nov 18, 2026 | |
| $259.57 Nov 18, 2026 | $25.2B | 87 5-pillar Nov 18, 2026 | |
| $443.89 Nov 18, 2026 | $240B | 84 5-pillar Nov 18, 2026 | |
| $29.83 Nov 19, 2026 | $12.5B | 84 5-pillar Nov 18, 2026 | |
| $100.72 Nov 18, 2026 | $129B | 81 5-pillar Nov 18, 2026 | |
| $318.15 Nov 18, 2026 | $121B | 80 5-pillar Nov 18, 2026 | |
| $101.47 Nov 19, 2026 | $19.2B | 79 5-pillar Nov 18, 2026 | |
| $29.27 Nov 19, 2026 | $28.6B | 78 5-pillar Nov 18, 2026 | |
| Boston Scientific (BSX) — this page | $42.99 | $62.3B | 77 |
| $168.98 Nov 18, 2026 | $210B | 72 5-pillar Nov 18, 2026 | |
| $227.56 Nov 19, 2026 | $160B | 71 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $44.00 – $71.00
- Consensus target
- $53.77
- Median target
- $50.50
Consensus record · Captured .
Measured against a quoted price of $42.99 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 4, 2026
- Transactions
- 22
- Identified insiders
- 9
- Purchases
- 6
- Sales
- 0
- Other transactions
- 16
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BSX in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.08% | $19.08M | Trimmed −1.1% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Boston Scientific (BSX)?
Boston Scientific Healthcare Stock: Key Questions Answered
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How does EluPro affect Boston Scientific’s cardiac rhythm management outlook?
Management expects cardiac rhythm management to remain flat over the full year, with modest improvement later as the fully launched EluPro begins contributing. Its performance is therefore a direct test of whether this product area can resume growth.
What sits inside Boston Scientific’s Cardiovascular business?
The portfolio includes coronary stents, interventional tools, intravascular imaging catheters, structural-heart therapies and devices for peripheral arterial and venous disease.
Which Boston Scientific products sit outside cardiovascular care?
MedSurg serves gastrointestinal, pulmonary, urological and pelvic-health applications, while the wider portfolio includes spinal-cord stimulation, deep-brain stimulation and other neurological therapies. These businesses diversify clinical exposure beyond heart and vascular procedures.
Did Boston Scientific’s latest sales gain reach diluted earnings?
Revenue, gross profit and operating result advanced from the preceding period, but net result and diluted earnings per share declined. Sales growth alone therefore did not translate into matching per-share progression.
What is the BSX stock price today?
The last price recorded for Boston Scientific Corporation (BSX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the BSX price target?
The analyst consensus price target for Boston Scientific Corporation (BSX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 42 figures on this page — 1 from SEC filings and earnings calls, 35 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold BSX
Funds in our ETF coverage that list BSX among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| BNY Mellon Women's Opportunities ETF (BKWO) | 2.57% |
